Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.
about
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trialNatural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewEffect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trialCardiovascular safety of anti-diabetic drugsPancreatic regulation of glucose homeostasisPeroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinomaFirst do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas.Disorders of glucose metabolism in patients infected with human immunodeficiency virus.Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Ongoing challenges in pharmacovigilance.Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditureHepatotoxicity of thiazolidinediones.Are all glitazones the same?Effect of structural modifications on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 ratsNon-alcoholic fatty liver: a common manifestation of a metabolic disorder.Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells.Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer.PPARγ Ligands Regulate Noncontractile and Contractile Functions of Airway Smooth Muscle: Implications for Asthma Therapy.Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones.Mechanisms of drug-induced liver injury.Mechanisms and outcomes of drug- and toxicant-induced liver toxicity in diabetes.Role of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats.PPARgamma, PTEN, and the Fight against Cancer.Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update.Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.Identification of PPARγ ligands with One-dimensional Drug Profile Matching.Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: ending the heartache.Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models.Important elements for the diagnosis of drug-induced liver injuryApplication of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.The safety of thiazolidinediones.The Current Knowledge of the Role of PPAR in Hepatic Ischemia-Reperfusion Injury.Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics.Endoplasmic reticulum stress in drug- and environmental toxicant-induced liver toxicity.Effect of thiazolidinediones on the erythropoeitic and germinal cells in the male wistar rats.The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.The need for a national infrastructure to improve the rational use of therapeutics.Current management of diabetes mellitus and future directions in care.
P2860
Q22242637-EE59DE56-EFC8-47F1-9984-6F38AC081D60Q24561401-39626CA9-EA68-4397-AECD-7D74D0035BEFQ24645513-640C4BCA-3FB2-4E47-90FF-4E89F7EE04B4Q26741082-687564C4-4D33-482C-A0C8-02B633255E0CQ26766485-510502EF-C0BD-45D2-97A5-605D1CAFA712Q28366616-780A381C-0F73-40BC-880A-904CE64BB986Q33845881-ACF03BDA-BD8C-406F-9566-1F4B8D3E0355Q33867088-5BBF9EE2-03B6-4DD8-BA45-AA418538CE40Q34092346-064A197F-2DCA-4863-A765-9C1D7F36B93CQ34294773-916DD4D2-D825-4D35-BEEE-58F7FA15884CQ34315432-FADE241C-24CD-4625-ACB4-9064BA897AA4Q34417013-15627726-5314-46F4-95AF-9E5B87C4F317Q34502676-0FA34A7C-C10B-4F75-8440-8E4118339E8FQ34570521-2575A14F-9BC0-4448-AE3D-7DB57F011FE0Q34580975-B5288E05-397F-4813-BE4B-3F365D71F7C1Q35218115-69C0689C-9B35-4B2D-AE3B-5122671AAA5CQ35538766-3711E655-73B7-4F35-934A-E689B828C143Q36067499-82494F26-3268-4842-9D6D-180D5FA6CDB8Q36187022-268F909B-11BF-4D91-99CD-9245EF8AA7DDQ36200396-BE335D98-3181-4EB5-A9B0-BC0FBAAAAB82Q36305927-288F0E9C-38E2-4EA8-AF2F-0C344D4FC784Q36439183-4BDB89EB-3DB8-4C97-9AAB-8BFEB2F5E629Q36871062-1E7C370E-C378-4FF4-87A4-5872FBB3BFFAQ36943606-26B5C9C9-0DF4-4BA2-8036-997682F1F1B0Q37014943-2569D64C-4045-453D-8E7B-D58CAC031BEEQ37142138-54064582-8EE4-40B9-93A2-D4D28913FC5CQ37149405-69E17022-99FC-4DD3-AFF9-3786E0CD129EQ37165170-35FD2B03-A98D-4F3E-85C3-F035A9FD6029Q37267783-65106A50-C042-407A-89ED-56F5B343B1A5Q37391731-FD77D6B5-3739-4AC8-BCE4-EA452225644DQ37512625-1E528BAA-0F34-4EFD-AB91-0EAD74557325Q37564187-1AF39097-786E-4292-9851-78D637A038A1Q37848841-507CE10A-C4A5-478A-B5DD-3D7B29284E4AQ38016858-3A1A72D7-C165-44E5-AD19-7C59D7011A66Q38151571-359DD91E-CD54-47CE-ACB9-FF1C6127900EQ38193602-874E2154-199D-44B4-923F-B0573D7CFD96Q38260621-E0A45AD3-768C-4F24-B177-7187E6B19AB7Q38273378-C77B72E4-5234-4AB8-9A38-1923A57FEA85Q38468151-0B341104-FFD7-45C0-9BF3-D24865E1F335Q38603504-887A27DF-CDBE-4D30-A5E2-F63935E0F375
P2860
Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Hepatotoxicity due to troglita ...... Food and Drug Administration.
@ast
Hepatotoxicity due to troglita ...... Food and Drug Administration.
@en
type
label
Hepatotoxicity due to troglita ...... Food and Drug Administration.
@ast
Hepatotoxicity due to troglita ...... Food and Drug Administration.
@en
prefLabel
Hepatotoxicity due to troglita ...... Food and Drug Administration.
@ast
Hepatotoxicity due to troglita ...... Food and Drug Administration.
@en
P2093
P1476
Hepatotoxicity due to troglita ...... Food and Drug Administration.
@en
P2093
Bonkovsky HL
Kohlroser J
Reichheld J
P304
P356
10.1111/J.1572-0241.2000.01707.X
P407
P577
2000-01-01T00:00:00Z